São Paulo, Brazil: The daily administration of CBD oil extracts does not aid COVID patients in their recovery from the disease, according to randomized placebo-controlled clinical trial data published in the journal Cannabis and Cannabinoid Research.
A team of Brazilian researchers affiliated with the National Institute for Science and Technology assessed the efficacy of the use of 300mg of CBD versus placebo in 91 patients with mild to moderate COVID symptoms. Participants consumed CBD daily for a period of 14 days in addition to their standard care.
Investigators reported, “Daily administration of 300 mg CBD for 14 days to patients with a recent diagnosis of COVID-19 with mild or moderate severity was safe but did not alter the clinical evolution in the first 28 days of follow-up.” Specifically, authors reported no differences in subjects’ viral load, levels of anxiety or depression, or in the “complete resolution of typical COVID-19 symptoms.”
They concluded, “Further trials with patients with different severity levels of COVID-19 and CBD doses are necessary to confirm the absence of effects of CBD in the clinical course of COVID-19 observed in our study.”
A separate clinical trial by the same research team evaluating whether CBD “could act as an effective preventive agent for chronic post-COVID-19 syndrome symptoms” is ongoing.
NORML has previously cautioned about the marketing of certain CBD products as potential agents for the treatment of COVID-19, citing a lack of human data substantiating its efficacy as an antiviral agent.
Full text of the study, “Cannabidiol for COVID-19 patients with mild to moderate symptoms: A randomized, double-blind, placebo-controlled clinical trial,” appears in Cannabis and Cannabinoid Research.